Evolving Therapeutic Options for Moderate-to-Severe Asthma: A Comprehensive 3-Dimensional Study

View Activity

FACULTY

Jonathan Corren, MD
Director, Allergy Medical Center
Associate Professor, Department of Internal Medicine
UCLA Medical Center
Los Angeles, CA

Michael E. Wechsler, MD, MMSc
Director, Asthma Program
Professor, Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with chronic or severe asthma.

TARGET AUDIENCE

This CME initiative is designed to meet the educational needs of pulmonologists, allergists, immunologists and primary care physicians who are involved in the healthcare of patients with severe asthma.

LEARNING OBJECTIVES

Upon completion of the CME activity, learners should be better able to:

  • Assess the causes of underlying inflammation in asthma, and resulting targets of therapy
  • Evaluate the level of asthma control, disease severity, and exacerbation risk to better drive appropriate treatment
  • Review currently-available and novel targeted therapies and their effect on treatment strategies for patients with moderate-to-severe asthma

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Corren has received consultant fees from Genentech, Novartis, and Sanofi – Regeneron.

Dr. Wechsler has received consulting fees from GlaxoSmithKline, Boehringer Ingelheim, Sanofi-Regeneron, AstraZeneca, Novartis, Boston Scientific, and Teva. He has also received research funding from Sanofi-Regeneron and AstraZeneca.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA Program Manager for Med Learning Group has nothing to disclose.
Cathy Herbert, MS Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, Dr. Corren and Dr. Wechsler may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: December 7, 2018

EXPIRATION DATE: December 7, 2019

View Activity

Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.